• Search
  • Advanced Search

Editorial

November 30, 2024


Editorial for JUO 2024 Vol. 22 No. 3 - Rethinking Urologic Oncology Surgery
Cheol Kwak
J Urol Oncol. 2024;22(3):185-187.

Original Article

November 30, 2024


Early Experience of the Single-Port Robotic Transvesical Radical Prostatectomy: Case Series
Jae Hoon Chung, Hwanik Kim, Woo Jin Bang, et al.
J Urol Oncol. 2024;22(3):188-195.

Purpose: This study evaluated the feasibility and safety of single-port transvesical robotic radical prostatectomy. Materials and Methods: Four patients underwent a transvesical robotic radical prostatectomy using a singleport robotic system. The...

Original Article

November 30, 2024


Simultaneous Prostate Target Biopsy Integrated With Radical Prostatectomy: A Pilot Study Omitting Preoperative Systematic Biopsy
Tae Young Park, Jae Young Hwang, Seong Woo Yun, et al.
J Urol Oncol. 2024;22(3):196-200.

Purpose: This study evaluates the viability of a new method that employs transperineal targeted biopsy with frozen section analysis immediately followed by robot-assisted radical prostatectomy (RARP), bypassing the traditional systematic...

Original Article

November 30, 2024


A Machine Learning Model for Prostate Cancer Prediction in Korean Men
Sukjung Choi, Beomgi So, Shane Oh, et al.
J Urol Oncol. 2024;22(3):201-210.

Purpose: Unnecessary prostate biopsies for detecting prostate cancer (PCa) should be minimized. Therefore, this study developed a machine learning (ML) model to predict PCa in Korean men and evaluated its...

Original Article

November 30, 2024


Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Abiraterone Clinical Trials
Matthew Rashid, Eli Oldham, Griffin K. Hughes, et al.
J Urol Oncol. 2024;22(3):211-223.

Purpose: Our study aimed to evaluate the risk and benefit profiles of clinical trials using abiraterone in cancer treatment. Materials and Methods: A comprehensive search was conducted on May 24, 2023,...

Brief Report

November 30, 2024


The Current Role of Metastasis-Directed Therapy for Oligometastatic Renal Cell Carcinoma
Hyung Joon Kim
J Urol Oncol. 2024;22(3):224-227.
Approximately 20% of newly diagnosed renal cell carcinoma (RCC) cases exhibit synchronous metastases, while 20% to 40% of initially localized RCC cases subsequently develop distant metastases after surgical intervention. In...

Invited Review

November 30, 2024


Exploring the Evolving Role of Metastasectomy in Advanced Renal Cell Carcinoma
Jongkyou Kwon, Sungun Bang, Kang Su Cho
J Urol Oncol. 2024;22(3):228-236.
In the treatment of metastatic lesions in advanced renal cell carcinoma (RCC), no clear consensus exists regarding whether immunotherapy should be combined with surgical resection or metastasectomy. Systemic therapies have...

Original Article

November 30, 2024


Clinical Application of Artificial Intelligence-Based Computed Tomography Analysis of Myosteatosis in Localized Renal Cell Carcinoma
Byeong Jin Kang, Kyung Hwan Kim, Seung Baek Hong, et al.
J Urol Oncol. 2024;22(3):237-245.

Purpose: Myosteatosis, defined as fat infiltration in muscle tissue, has been linked to poor outcomes in various cancers. However, the prognostic impact of myosteatosis on renal cell carcinoma (RCC) remains...

Invited Review

November 30, 2024


The Emerging Treatment of BCG (Bacillus Calmette-Guérin)-Unresponsive Non–Muscle-Invasive Bladder Cancer
Jong Ho Park, Jong Jin Oh
J Urol Oncol. 2024;22(3):246-255.
Bacillus Calmette-Guérin (BCG) remains the cornerstone in the treatment of high-risk non-muscle-invasive bladder cancer (NMIBC), effectively preventing recurrence and progression. Unfortunately, a significant proportion of patients are classified as BCG-unresponsive,...

Invited Review

November 30, 2024


Trimodal Therapy in the Treatment of Muscle-Invasive Bladder Cancer
Yongsoo Jo, Hyeong Dong Yuk
J Urol Oncol. 2024;22(3):256-267.

This review examines the evolution, clinical efficacy, and future directions of trimodal therapy (TMT) as a bladder-preserving treatment option for muscle-invasive bladder cancer. A nonsystematic literature search was conducted on...

Review Article

November 30, 2024


Artificial Intelligence: The Latest Advances in the Diagnosis of Bladder Cancer
Satyendra Singh, Ram Mohan Shukla
J Urol Oncol. 2024;22(3):268-280.

Bladder cancer remains a significant health challenge. Early and accurate diagnoses are crucial for effective treatment and improved patient outcomes. In recent years, artificial intelligence (AI) has emerged as a...

Correction

September 11, 2024


Correction: Addendum of Informed Consent Statements
J Urol Oncol. 2024;22(3):281-281.

Expression of Concern

November 30, 2024


Expression of Concern: Rare Ewingoid Dedifferentiated Liposarcoma of the Spermatic Cord Causing Testicular Artery Compression: A Case Report
J Urol Oncol. 2024;22(3):282-282.
Current Issue
Volume 22(3); Nov 2024
Articles in E-pub version are posted online ahead of regular printed publication.

Journal of
Urologic Oncology

Print ISSN: 2951-603X
Online ISSN: 2982-7043

Editorial Office
Department of Urology, Seoul National University Hospital, Seoul National University College of Medicine,
101 Daehak-ro, Jongno-gu, Seoul 03080, Korea
TEL: +82-2-2072-0817,   FAX: +82-2-742-4665   Email: journal@e-juo.org
Korean Urological Oncology Society
50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea
Tel: +82-2-704-8574, E-mail: leeseh@yuhs.ac

Copyright © The Korean Urological Oncology Society.

Developed in M2PI